Vident Investment Advisory LLC increased its stake in shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) by 46.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 587,255 shares of the biotechnology company’s stock after purchasing an additional 187,195 shares during the quarter. Vident Investment Advisory LLC owned approximately 0.41% of ZIOPHARM Oncology worth $1,774,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of ZIOP. BlackRock Inc. grew its holdings in ZIOPHARM Oncology by 8.5% in the 2nd quarter. BlackRock Inc. now owns 9,167,740 shares of the biotechnology company’s stock valued at $27,686,000 after buying an additional 717,804 shares during the period. UBS Group AG grew its holdings in ZIOPHARM Oncology by 35.3% in the 1st quarter. UBS Group AG now owns 872,376 shares of the biotechnology company’s stock valued at $3,420,000 after buying an additional 227,812 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in ZIOPHARM Oncology by 7.5% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 713,837 shares of the biotechnology company’s stock valued at $2,156,000 after buying an additional 49,615 shares during the period. Wells Fargo & Company MN grew its holdings in ZIOPHARM Oncology by 25.8% in the 1st quarter. Wells Fargo & Company MN now owns 251,068 shares of the biotechnology company’s stock valued at $985,000 after buying an additional 51,499 shares during the period. Finally, Russell Investments Group Ltd. purchased a new stake in ZIOPHARM Oncology in the 1st quarter valued at about $911,000. Hedge funds and other institutional investors own 39.30% of the company’s stock.

Several research firms have commented on ZIOP. BidaskClub cut ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a report on Tuesday, June 26th. JPMorgan Chase & Co. cut ZIOPHARM Oncology from a “neutral” rating to an “underweight” rating in a report on Monday, June 18th. Finally, ValuEngine upgraded ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $5.25.

NASDAQ ZIOP opened at $2.72 on Monday. The stock has a market capitalization of $395.82 million, a PE ratio of -5.13 and a beta of 1.39. ZIOPHARM Oncology Inc. has a 1-year low of $2.23 and a 1-year high of $6.60.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). sell-side analysts anticipate that ZIOPHARM Oncology Inc. will post -0.5 earnings per share for the current fiscal year.

ZIOPHARM Oncology Profile

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.

Featured Story: Understanding Analyst Ratings

Institutional Ownership by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.